| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Divisions of Nutritional Carcinogenesis [C. V. R., B. S., B. S. R.], Pathology and Toxicology [A. R.], and Epidemiology [E. Z.], American Health Foundation, Valhalla, New York 10595, and Chemoprevention Branch, Division of Cancer Control and Prevention, National Cancer Institute, Bethesda, Maryland 20892 [G. K., V. S.]
Epidemiological and laboratory animal model studies have suggested that nonsteroidal anti-inflammatory drugs reduce the risk of development of colon cancer. The present study was designed to investigate the chemopreventive action of 160 and 320 ppm (equivalent to 40 and 80% maximum tolerated doses) sulindac, a nonsteroidal anti-inflammatory drug, fed during initiation and postinitiation stages and 320 ppm sulindac fed during promotion/progression stages of azoxymethane-induced colon carcinogenesis in male F344 rats. Also investigated was the modulating effect of this agent on the colonic mucosal and tumor phospholipase A2, phosphatidylinositol-specific phospholipase C, lipoxygenase, and cyclooxygenase activities. At 5 weeks of age, groups of male F344 rats were fed control diet or diets containing 160 and 320 ppm of sulindac. At 7 weeks of age, all animals except those in the vehicle-treated groups were given two weekly s.c. injections of azoxymethane at a dose rate of 15 mg/kg body weight/week. Animals intended for tumor promotion/progression study were administered 320 ppm of sulindac in diet starting at 14 weeks after a second azoxymethane treatment. All animals continued on their respective dietary regimen until the termination of the experiment at 52 weeks after the carcinogen treatment. Colonic tumors were evaluated histopathologically. Colonic mucosa and tumors were analyzed for phospholipase A2, phosphatidylinositol-specific phospholipase C, prostaglandin E2, cyclooxygenase, and lipoxygenase activities. The levels of sulindac and its metabolites in stomach, cecal, and fecal contents and in serum were analyzed. The results indicate that dietary sulindac at 160 and 320 ppm levels inhibited the incidence of invasive and nonivasive adenocarcinomas of the colon (P < 0.01–0.001) as well as their multiplicity (P < 0.01–0.0001) in a dose-dependent manner. Also, feeding sulindac during promotion/progression stages significantly suppressed the incidence (P < 0.0001) and multiplicity (P < 0.0001) of colonic adenocarcinomas. Dietary sulindac also suppressed the colon tumor volume by >52–62% compared to the control diet. Dietary sulindac significantly decreased the activities of phosphatidylinositol-specific phospholipase C (32–51%) and levels of prostaglandin E2 (>40%) in the colonic mucosa and tumors, but it had no significant (P > 0.05) effect on phospholipase A2 activity. The formation of cyclooxygenase metabolites, particularly prostaglandin E2, prostaglandin F2
, prostaglandin D2, 6-ketoprostaglandin F1, and thromboxane B2, and lipoxygenase metabolites such as 8(S)- and 12(S)-hydroxyeicosatetraenoic acids were significantly reduced in colonic mucosa and tumors of animals fed 320 ppm sulindac. Also, animals fed 320 ppm sulindac showed increased levels of microbial metabolites of sulindac in cecal and fecal contents and in serum as compared to those fed 160 ppm sulindac. Although the exact mechanism by which sulindac inhibits colon tumorigenesis remains to be elucidated, it is likely that its chemopreventive action, at least in part, may be related to the modulation of arachidonic acid metabolism.
1 Supported by USPHS Grants CN85095-05 and CA17613 awarded by the National Cancer Institute.
2 To whom requests for reprints should be addressed.
Received 11/21/94. Accepted 2/ 2/95.
This article has been cited by other articles:
|
|
 |
|
  N. Wakimoto, I. Wolf, D. Yin, J. O'Kelly, T. Akagi, L. Abramovitz, K. L. Black, H.-H. Tai, and H. P. Koeffler Nonsteroidal Anti-inflammatory Drugs Suppress Glioma via 15-Hydroxyprostaglandin Dehydrogenase Cancer Res., September 1, 2008; 68(17): 6978 - 6986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Papadimitrakopoulou, W. N. William Jr., A. J. Dannenberg, S. M. Lippman, J. J. Lee, F. G. Ondrey, D. E. Peterson, L. Feng, A. Atwell, A. K. El-Naggar, et al. Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions Clin. Cancer Res., April 1, 2008; 14(7): 2095 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Ciolino, C. J. MacDonald, O. S. Memon, S. E. Bass, and G. C. Yeh Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro Carcinogenesis, August 1, 2006; 27(8): 1586 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Swamy, J. M.R. Patlolla, V. E. Steele, L. Kopelovich, B. S. Reddy, and C. V. Rao Chemoprevention of Familial Adenomatous Polyposis by Low Doses of Atorvastatin and Celecoxib Given Individually and in Combination to APCMin Mice. Cancer Res., July 15, 2006; 66(14): 7370 - 7377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. V. Rao, B. S. Reddy, V. E. Steele, C-X Wang, X. Liu, N. Ouyang, J. M.R. Patlolla, B. Simi, L. Kopelovich, and B. Rigas Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol. Cancer Ther., June 1, 2006; 5(6): 1530 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Xiao, A. Deguchi, G. G. Gundersen, B. Oehlen, L. Arnold, and I. B. Weinstein The sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by causing microtubule depolymerization Mol. Cancer Ther., January 1, 2006; 5(1): 60 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Moon, F. G. Bottone Jr., M. F. McEntee, and T. E. Eling Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1 Mol. Cancer Ther., October 1, 2005; 4(10): 1551 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minami, M. Adachi, R. Kawamura, Y. Zhang, Y. Shinomura, and K. Imai Sulindac Enhances the Proteasome Inhibitor Bortezomib-Mediated Oxidative Stress and Anticancer Activity Clin. Cancer Res., July 15, 2005; 11(14): 5248 - 5256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Koornstra, F. E.M. Rijcken, C. N.A.M. Oldenhuis, N. Zwart, T. van der Sluis, H. Hollema, E. G.E. deVries, J. J. Keller, J. A. Offerhaus, F. M. Giardiello, et al. Sulindac Inhibits {beta}-Catenin Expression in Normal-Appearing Colon of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis Patients Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1608 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15 Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Nam, K.-B. Hahm, S.-Y. Oh, M. Yeo, S.-U. Han, B. Ahn, Y.-B. Kim, J. S. Kang, D. D. Jang, K.-H. Yang, et al. The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter pylori-Associated Gastric Cancer Development in a Mouse Model Clin. Cancer Res., December 1, 2004; 10(23): 8105 - 8113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Shoji, M Takahashi, T Kitamura, K Watanabe, T Kawamori, T Maruyama, Y Sugimoto, M Negishi, S Narumiya, T Sugimura, et al. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development Gut, August 1, 2004; 53(8): 1151 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P J Hu, J Yu, Z R Zeng, W K Leung, H L Lin, B D Tang, A H C Bai, and J J Y Sung Chemoprevention of gastric cancer by celecoxib in rats Gut, February 1, 2004; 53(2): 195 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Swamy, I. Cooma, J. M.R. Patlolla, B. Simi, B. S. Reddy, and C. V. Rao Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment Mol. Cancer Ther., February 1, 2004; 3(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Chang, C. H. Liu, R. Conway, D. K. Han, K. Nithipatikom, O. C. Trifan, T. F. Lane, and T. Hla From the Cover: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression PNAS, January 13, 2004; 101(2): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Babbar, N. A. Ignatenko, R. A. Casero Jr., and E. W. Gerner Cyclooxygenase-independent Induction of Apoptosis by Sulindac Sulfone Is Mediated by Polyamines in Colon Cancer J. Biol. Chem., November 28, 2003; 278(48): 47762 - 47775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Herendeen and C. Lindley Use of NSAIDs for the Chemoprevention of Colorectal Cancer Ann. Pharmacother., November 1, 2003; 37(11): 1664 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Murakami, K. Nakashima, D. Kamei, S. Masuda, Y. Ishikawa, T. Ishii, Y. Ohmiya, K. Watanabe, and I. Kudo Cellular Prostaglandin E2 Production by Membrane-bound Prostaglandin E Synthase-2 via Both Cyclooxygenases-1 and -2 J. Biol. Chem., September 26, 2003; 278(39): 37937 - 37947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kamei, M. Murakami, Y. Nakatani, Y. Ishikawa, T. Ishii, and I. Kudo Potential Role of Microsomal Prostaglandin E Synthase-1 in Tumorigenesis J. Biol. Chem., May 23, 2003; 278(21): 19396 - 19405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Corpet and F. Pierre Point: From Animal Models to Prevention of Colon Cancer. Systematic Review of Chemoprevention in Min Mice and Choice of the Model System Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 391 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fukuda, B. Kelly, and G. L. Semenza Vascular Endothelial Growth Factor Gene Expression in Colon Cancer Cells Exposed to Prostaglandin E2 Is Mediated by Hypoxia-inducible Factor 1 Cancer Res., May 1, 2003; 63(9): 2330 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Fischer, C. J. Conti, J. Viner, C.M. Aldaz, and R. A. Lubet Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice Carcinogenesis, May 1, 2003; 24(5): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E.M. Dommels, M. M.G. Haring, N. G.M. Keestra, G. M. Alink, P. J. van Bladeren, and B. van Ommen The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE2 synthesis and cytotoxicity in human colorectal carcinoma cell lines Carcinogenesis, March 1, 2003; 24(3): 385 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yang, K. Fan, N. Kurihara, H. Shinozaki, B. Rigas, L. Augenlicht, L. Kopelovich, W. Edelmann, R. Kucherlapati, and M. Lipkin Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations Carcinogenesis, March 1, 2003; 24(3): 605 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wick, G. Hurteau, C. Dessev, D. Chan, M. W. Geraci, R. A. Winn, L. E. Heasley, and R. A. Nemenoff Peroxisome Proliferator-Activated Receptor-gamma Is a Target of Nonsteroidal Anti-Inflammatory Drugs Mediating Cyclooxygenase-Independent Inhibition of Lung Cancer Cell Growth Mol. Pharmacol., November 1, 2002; 62(5): 1207 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Hardman Omega-3 Fatty Acids to Augment Cancer Therapy J. Nutr., November 1, 2002; 132(11): 3508S - 3512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Tao, P. M. Kramer, W. Wang, S. Yang, R. A. Lubet, V. E. Steele, and M. A. Pereira Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents Carcinogenesis, September 1, 2002; 23(9): 1447 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Tiano, C. D. Loftin, J. Akunda, C. A. Lee, J. Spalding, A. Sessoms, D. B. Dunson, E. G. Rogan, S. G. Morham, R. C. Smart, et al. Deficiency of Either Cyclooxygenase (COX)-1 or COX-2 Alters Epidermal Differentiation and Reduces Mouse Skin Tumorigenesis Cancer Res., June 1, 2002; 62(12): 3395 - 3401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Pentland Cyclooxygenase Inhibitors for Skin Cancer Prevention: Are They Beneficial Enough? Arch Dermatol, June 1, 2002; 138(6): 823 - 824. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsunozaki, K. Yoshinaga, J. Kumagai, and K. Sugihara Cyclooxygenase-2 Overexpression in Colorectal Cancer is Associated with Non-polypoid Growth Jpn. J. Clin. Oncol., May 1, 2002; 32(5): 167 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-M. Karaguni, P. Herter, P. Debruyne, S. Chtarbova, A. Kasprzynski, U. Herbrand, M-R. Ahmadian, K.-H. Glusenkamp, G. Winde, M. Mareel, et al. The New Sulindac Derivative IND 12 Reverses Ras-induced Cell Transformation Cancer Res., March 1, 2002; 62(6): 1718 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Berman, U. N. Verma, G. Harburg, J. D. Minna, M. H. Cobb, and R. B. Gaynor Sulindac Enhances Tumor Necrosis Factor-{alpha}-mediated Apoptosis of Lung Cancer Cell Lines by Inhibition of Nuclear Factor-{kappa}B Clin. Cancer Res., February 1, 2002; 8(2): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. A. Adamson, D. Frew, R. Tatoud, C. R. Wolf, and C. N. A. Palmer Diclofenac Antagonizes Peroxisome Proliferator-Activated Receptor-gamma Signaling Mol. Pharmacol., January 1, 2002; 61(1): 7 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. TEGEDER, J. PFEILSCHIFTER, and G. GEISSLINGER Cyclooxygenase-independent actions of cyclooxygenase inhibitors FASEB J, October 1, 2001; 15(12): 2057 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, Q. He, M. J. Hillman, R. Rong, and M. S. Sheikh Sulindac Sulfide-induced Apoptosis Involves Death Receptor 5 and the Caspase 8-dependent Pathway in Human Colon and Prostate Cancer Cells Cancer Res., September 1, 2001; 61(18): 6918 - 6924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yang, A. Velcich, J. Mariadason, C. Nicholas, G. Corner, M. Houston, W. Edelmann, R. Kucherlapati, P. R. Holt, and L. H. Augenlicht p21WAF1/cip1 Is an Important Determinant of Intestinal Cell Response to Sulindac in Vitro and in Vivo Cancer Res., August 1, 2001; 61(16): 6297 - 6302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. RODRIGUES, Q.-D. NGUYEN, S. FAIVRE, E. BRUYNEEL, L. THIM, B. WESTLEY, F. MAY, G. FLATAU, M. MAREEL, C. GESPACH, et al. Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways FASEB J, July 1, 2001; 15(9): 1517 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kojima, T. Morisaki, A. Uchiyama, F. Doi, R. Mibu, M. Katano, and M. Tanaka Association of Enhanced Cyclooxygenase-2 Expression With Possible Local Immunosuppression in Human Colorectal Carcinomas Ann. Surg. Oncol., June 1, 2001; 8(5): 458 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vogiagis, W. Brown, E. M. Glare, and P. E. O'Brien Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels Carcinogenesis, June 1, 2001; 22(6): 869 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shono, P. J. Tofilon, J. M. Bruner, O. Owolabi, and F. F. Lang Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations Cancer Res., June 1, 2001; 61(11): 4375 - 4381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Rao, C-Q. Wang, B. Simi, J. G. Rodriguez, I. Cooma, K. El-Bayoumy, and B. S. Reddy Chemoprevention of Colon Cancer by a Glutathione Conjugate of 1,4-Phenylenebis(methylene)selenocyanate, a Novel Organoselenium Compound with Low Toxicity Cancer Res., May 1, 2001; 61(9): 3647 - 3652. [Abstract] [Full Text]
|
|
|
|
|
|
C. V. Rao, Y. Hirose, C. Indranie, and B. S. Reddy Modulation of Experimental Colon Tumorigenesis by Types and Amounts of Dietary Fatty Acids Cancer Res., March 1, 2001; 61(5): 1927 - 1933. [Abstract] [Full Text]
|
|
|
|
|
|
M. Oshima, N. Murai, S. Kargman, M. Arguello, P. Luk, E. Kwong, M. M. Taketo, and J. F. Evans Chemoprevention of Intestinal Polyposis in the Apc{{Delta}}716 Mouse by Rofecoxib, a Specific Cyclooxygenase-2 Inhibitor Cancer Res., February 1, 2001; 61(4): 1733 - 1740. [Abstract] [Full Text]
|
|
|
|
|
|
S Chariyalertsak, V Sirikulchayanonta, D Mayer, A Kopp-Schneider, G Furstenberger, F Marks, and K Muller-Decker Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma Gut, January 1, 2001; 48(1): 80 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shirin, J. T. Pinto, Y. Kawabata, J.-W. Soh, T. Delohery, S. F. Moss, V. Murty, R. S. Rivlin, P. R. Holt, and I. B. Weinstein Antiproliferative Effects of S-Allylmercaptocysteine on Colon Cancer Cells When Tested Alone or in Combination with Sulindac Sulfide Cancer Res., January 1, 2001; 61(2): 725 - 731. [Abstract] [Full Text]
|
|
|
|
|
|
Y Kishimoto, N Takata, T Jinnai, T Morisawa, G Shiota, H Kawasaki, and J Hasegawa Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane Gut, December 1, 2000; 47(6): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Ullrich and H. J. Lyons Mechanisms Involved in the Immunotoxicity Induced by Dermal Application of JP-8 Jet Fuel Toxicol. Sci., December 1, 2000; 58(2): 290 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Lawson, N. A. Ignatenko, G. A. Piazza, H. Cui, and E. W. Gerner Influence of K-ras Activation on the Survival Responses of Caco-2 Cells to the Chemopreventive Agents Sulindac and Difluoromethylornithine Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1155 - 1162. [Abstract] [Full Text]
|
|
|
|
|
|
P. C. Chulada, M. B. Thompson, J. F. Mahler, C. M. Doyle, B. W. Gaul, C. Lee, H. F. Tiano, S. G. Morham, O. Smithies, and R. Langenbach Genetic Disruption of Ptgs-1, as well as of Ptgs-2, Reduces Intestinal Tumorigenesis in Min Mice Cancer Res., September 1, 2000; 60(17): 4705 - 4708. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy, Y. Hirose, L. A. Cohen, B. Simi, I. Cooma, and C. V. Rao Preventive Potential of Wheat Bran Fractions against Experimental Colon Carcinogenesis: Implications for Human Colon Cancer Prevention Cancer Res., September 1, 2000; 60(17): 4792 - 4797. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Wilson and C. S. Potten The Effect of Exogenous Prostaglandin Administration on Tumor Size and Yield in Min/+ Mice Cancer Res., August 1, 2000; 60(16): 4645 - 4653. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. A. Janne and R. J. Mayer Chemoprevention of Colorectal Cancer N. Engl. J. Med., June 29, 2000; 342(26): 1960 - 1968. [Full Text] [PDF]
|
|
|
|
|
|
C. Petersen, S. Petersen, L. Milas, F. F. Lang, and P. J. Tofilon Enhancement of Intrinsic Tumor Cell Radiosensitivity Induced by a Selective Cyclooxygenase-2 Inhibitor Clin. Cancer Res., June 1, 2000; 6(6): 2513 - 2520. [Abstract] [Full Text]
|
|
|
|
|
|
H. Sasai, M. Masaki, and K. Wakitani Suppression of polypogenesis in a new mouse strain with a truncated Apc{Delta}474 by a novel COX-2 inhibitor, JTE-522 Carcinogenesis, May 1, 2000; 21(5): 953 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Rao, I. Cooma, J. G.R. Rodriguez, B. Simi, K. El-Bayoumy, and B. S. Reddy Chemoprevention of familial adenomatous polyposis development in the APCmin mouse model by 1,4-phenylene bis(methylene)selenocyanate Carcinogenesis, April 1, 2000; 21(4): 617 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. ZEIDLER, M. CSANADY, O. GIRES, S. LANG, B. SCHMITT, and B. WOLLENBERG Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1 FASEB J, April 1, 2000; 14(5): 661 - 668. [Abstract] [Full Text]
|
|
|
|
|
|
R. F. Jacoby, C. E. Cole, K. Tutsch, M. A. Newton, G. Kelloff, E. T. Hawk, and R. A. Lubet Chemopreventive Efficacy of Combined Piroxicam and Difluoromethylornithine Treatment of Apc Mutant Min Mouse Adenomas, and Selective Toxicity against Apc Mutant Embryos Cancer |
